Apellis Pharmaceuticals, Inc.APLSEarnings & Financial Report
Nasdaq
NextMar 31, 2026
APLS Q3 2025 Key Financial Metrics
Revenue
$458.6M
Gross Profit
N/A
Operating Profit
$223.2M
Net Profit
$215.7M
Gross Margin
N/A
Operating Margin
48.7%
Net Margin
47.0%
YoY Growth
133.0%
EPS
$1.67
Financial Flow
Apellis Pharmaceuticals, Inc. Q3 2025 Financial Summary
Apellis Pharmaceuticals, Inc. reported revenue of $458.6M for Q3 2025, with a net profit of $215.7M (47.0% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $458.6M |
|---|---|
| Net Profit | $215.7M |
| Gross Margin | N/A |
| Operating Margin | 48.7% |
| Report Period | Q3 2025 |
Apellis Pharmaceuticals, Inc. Annual Revenue by Year
Apellis Pharmaceuticals, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $781.4M).
| Year | Annual Revenue |
|---|---|
| 2024 | $781.4M |
| 2023 | $396.6M |
| 2022 | $75.4M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $146.4M | $172.3M | $199.7M | $196.8M | $212.5M | $166.8M | $178.5M | $458.6M |
| YoY Growth | 545.9% | 284.3% | 110.3% | 78.3% | 45.2% | -3.2% | -10.6% | 133.0% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $788.7M | $831.9M | $904.5M | $901.9M | $885.1M | $807.3M | $821.4M | $1.06B |
| Liabilities | $594.2M | $565.3M | $640.2M | $664.7M | $656.5M | $643.1M | $665.1M | $657.6M |
| Equity | $194.5M | $266.7M | $264.3M | $237.1M | $228.5M | $164.2M | $156.3M | $401.2M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-97.9M | $-133.0M | $-8.3M | $34.1M | $19.4M | $-53.4M | $4.4M | $108.5M |